How to buy Acceleron Pharma stock - 14 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Acceleron Pharma stock

Own Acceleron Pharma stock in just a few minutes.

Acceleron Pharma Inc is a biotechnology business based in the US. Acceleron Pharma shares (XLRN) are listed on the NASDAQ and all prices are listed in US Dollars. Acceleron Pharma employs 312 staff and has a trailing 12-month revenue of around USD$92.5 million.

How to buy shares in Acceleron Pharma

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Acceleron Pharma. Find the stock by name or ticker symbol: XLRN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Acceleron Pharma reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Acceleron Pharma, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Acceleron Pharma. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Acceleron Pharma share price

Use our graph to track the performance of XLRN stocks over time.

Acceleron Pharma shares at a glance

Information last updated 2021-04-09.
52-week rangeUSD$85.32 - USD$146.15
50-day moving average USD$134.7551
200-day moving average USD$122.7409
Wall St. target priceUSD$153.23
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.44

Buy Acceleron Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Acceleron Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Acceleron Pharma financials

Revenue TTM USD$92.5 million
Gross profit TTM USD$-81,394,000
Return on assets TTM -14.55%
Return on equity TTM -25.45%
Profit margin -179.45%
Book value $14.161
Market capitalisation USD$7.8 billion

TTM: trailing 12 months

Shorting Acceleron Pharma shares

There are currently 2.4 million Acceleron Pharma shares held short by investors – that's known as Acceleron Pharma's "short interest". This figure is 9.9% up from 2.2 million last month.

There are a few different ways that this level of interest in shorting Acceleron Pharma shares can be evaluated.

Acceleron Pharma's "short interest ratio" (SIR)

Acceleron Pharma's "short interest ratio" (SIR) is the quantity of Acceleron Pharma shares currently shorted divided by the average quantity of Acceleron Pharma shares traded daily (recently around 375027.95698925). Acceleron Pharma's SIR currently stands at 6.51. In other words for every 100,000 Acceleron Pharma shares traded daily on the market, roughly 6510 shares are currently held short.

However Acceleron Pharma's short interest can also be evaluated against the total number of Acceleron Pharma shares, or, against the total number of tradable Acceleron Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acceleron Pharma's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Acceleron Pharma shares in existence, roughly 40 shares are currently held short) or 0.0536% of the tradable shares (for every 100,000 tradable Acceleron Pharma shares, roughly 54 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Acceleron Pharma.

Find out more about how you can short Acceleron Pharma stock.

Acceleron Pharma share dividends

We're not expecting Acceleron Pharma to pay a dividend over the next 12 months.

Acceleron Pharma share price volatility

Over the last 12 months, Acceleron Pharma's shares have ranged in value from as little as $85.32 up to $146.15. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acceleron Pharma's is 0.4071. This would suggest that Acceleron Pharma's shares are less volatile than average (for this exchange).

Acceleron Pharma overview

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site